3 results match your criteria: "Department of Non-communicable Disease Epidemiology London School of Hygiene and Tropical Medicine London[Affiliation]"
Comparison of Effectiveness Among Different Sodium-Glucose Cotransoporter-2 Inhibitors According to Underlying Conditions: A Network Meta-Analysis of Randomized Controlled Trials.
J Am Heart Assoc
February 2024
Division of Cardiology Montefiore Medical Center, Albert Einstein College of Medicine New York NY.
Article Synopsis
- The study analyzed the effectiveness and safety of five SGLT2 inhibitors across different patient backgrounds, specifically focusing on cardiovascular death and hospitalizations for heart failure as primary outcomes.
- It included data from 21 randomized controlled trials with nearly 100,000 participants, revealing that while most SGLT2 inhibitors had similar efficacy, empagliflozin and dapagliflozin showed lower risks of acute kidney injury compared to sotagliflozin.
- The findings suggest that there are no major differences in safety outcomes among the SGLT2 inhibitors, but empagliflozin may be particularly beneficial for patients without chronic kidney disease, indicating a need for further research.
Background Acute COVID-19-related myocardial, pulmonary, and vascular pathology and how these relate to each other remain unclear. To our knowledge, no studies have used complementary imaging techniques, including molecular imaging, to elucidate this. We used multimodality imaging and biochemical sampling in vivo to identify the pathobiology of acute COVID-19.
View Article and Find Full Text PDFTrials of interventions that aim to slow disease progression may analyze a continuous outcome by comparing its change over time-its slope-between the treated and the untreated group using a linear mixed model. To perform a sample-size calculation for such a trial, one must have estimates of the parameters that govern the between- and within-subject variability in the outcome, which are often unknown. The algebra needed for the sample-size calculation can also be complex for such trial designs.
View Article and Find Full Text PDF